SV 293 [1-([5-methoxy-1H-indol-3-yl]methyl)-4-(4-[methylthio]​phenyl)piperidin-4-ol] binds with 100-fold higher affinity to human D2 receptors compared to the human D3 and D4 dopamine receptor subtypes. We investigated the intrinsic efficacy of this compound at the D2 dopamine receptor subtype using both: (1) a forskolin-dependent adenylyl cyclase inhibition assay and (2) an electrophysiological assay for evaluating coupling to G-protein-coupled inwardly rectifying potassium channels. In both assays SV 293 was found to be a neutral antagonist capable of blocking the effects of the full D2-like receptor agonist quinpirole. Based upon these results we propose that SV 293 is a useful pharmacological tool that can be used for both in vitro and in vivo studies to investigate the role of D2-like dopamine receptor subtypes in neurological, neuropsychiatric and movement disorders where dopaminergic pathways have been implicated.

Keywords:
Dopamine receptors, Antagonist binding, G-protein-coupled inwardly rectifying potassium, Patch clamp
1.
Missale C, Nash SR, Robinson SW, et al: Dopamine receptors: from structure to function. Physiol Rev 1998;78:189-225.
2.
Kapur S, Mamo D: Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1081-1090.
3.
Jardemark K, Wadenberg ML, Grillner P, Svensson TH: Dopamine D3 and D4 receptor antagonists in the treatment of schizophrenia. Curr Opin Investig Drugs 2002;3:101-105.
4.
Korczyn AD: Dopaminergic drugs in development for Parkinson's disease. Adv Neurol 2003;91:267-271.
5.
Kumar R, Riddle LR, Griffin SA, et al: Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology 2009;56:956-969.
6.
Nieoullon A: Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002;67:53-83.
7.
Nader MA, Morgan D, Gage HD, et al: PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat Neurosci 2006;9:1050-1056.
8.
Volkow ND, Fowler JS, Wang GJ: Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav Pharmacol 2002;13:355-366.
9.
Vallone D, Picetti R, Borrelli E: Structure and function of dopamine receptors. Neurosci Biobehav Rev 2000;24:125-132.
10.
Huff RM, Chio CL, Lajiness ME, Goodman LV: Signal transduction pathways modulated by D2-like dopamine receptors. Adv Pharmacol 1998;42:454-457.
11.
Kuzhikandathil EV, Westrich L, Bakhos S, Pasuit J: Identification and characterization of novel properties of the human D3 dopamine receptor. Mol Cell Neurosci 2004;26:144-155.
12.
Neve KA, Seamans JK, Trantham-Davidson H: Dopamine receptor signaling. J Recept Signal Transduct Res 2004;24:165-205.
13.
Senogles SE: D2s dopamine receptor mediates phospholipase D and antiproliferation. Mol Cell Endocrinol 2003;209:61-69.
14.
Joyce JN: Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 2001;90:231-259.
15.
Kim KM, Valenzano KJ, Robinson SR, et al: Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins. J Biol Chem 2001;276:37409-37414.
16.
Chu W, Tu Z, McElveen E, et al: Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem 2005;13:77-87.
17.
Huang Y, Luedtke RR, Freeman RA, Wu L, Mach RH: Synthesis and structure-activity relationships of naphthamides as dopamine D3 receptor ligands. J Med Chem 2001;44:1815-1826.
18.
Mach RH, Huang Y, Freeman RA, et al: Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands. Bioorg Med Chem Lett 2004;14:195-202.
19.
Newman AH, Grundt P, Nader MA: Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem 2005;48:3663-3679.
20.
Canales JJ, Iversen SD: Psychomotor-activating effects mediated by dopamine D2 and D3 receptors in the nucleus accumbens. Pharmacol Biochem Behav 2000;67:161-168.
21.
Witkin JM, Dijkstra D, Levant B, et al: Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-enzopyrano[4, 3-b]-1,4-o xazin-9-ol [(+)-PD 128,907]. J Pharmacol Exp Ther 2004;308:957-964.
22.
Gendreau PL, Petitto JM, Petrova A, et al: D3 and D2 dopamine receptor agonists differentially modulate isolation-induced social-emotional reactivity in mice. Behav Brain Res 2000;114:107-117.
23.
Vangveravong S, McElveen E, Taylor M, et al: Synthesis and characterization of selective dopamine D2 receptor antagonists. Bioorg Med Chem 2006;14:815-825.
24.
Su YF, Cubeddu L, Perkins JP: Regulation of adenosine 3′:5′-monophosphate content of human astrocytoma cells: desensitization to catecholamines and prostaglandins. J Cyclic Nucleotide Res 1976;2:257-270.
25.
Luedtke RR, Freeman RA, Boundy VA, et al: Characterization of 125I-IABN, a novel azabicyclononane benzamide selective for D2-like dopamine receptors. Synapse 2000;38:438-449.
26.
Taylor M, Grundt P, Griffin SA, et al: Dopamine D3 receptor selective ligands with varying intrinsic efficacies at adenylyl cyclase inhibition and mitogenic signaling pathways. Synapse 2010;64:251-266.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.